Chandra Bhagat

Why is Chandra Bhagat Pharma Ltd falling/rising?

As of 01-Sep, Chandra Bhagat Pharma Ltd's stock price is stable at 50.40, with a positive short-term performance but concerning trends in trading activity and investor participation. Despite outperforming the Sensex recently, the stock's erratic trading and declining delivery volume suggest a cautious outlook ahead.

As of 01-Sep, Chandra Bhagat Pharma Ltd's stock price is currently stable at 50.40, showing no change (0.00%). Despite this stability, the stock has demonstrated a positive performance over various periods, particularly in the short term, with a 1-week increase of 1.00% and a significant 1-month rise of 32.91%. This contrasts sharply with the Sensex, which has declined by 0.92% over the same week and 1.47% over the month, indicating that Chandra Bhagat Pharma Ltd is outperforming the broader market.<BR><BR>However, there are some concerning trends that may affect future performance. The stock has experienced erratic trading, not trading on 5 out of the last 20 days, which suggests a lack of consistent investor interest. Additionally, there has been a notable decline in delivery volume, which fell by 16.67% compared to the 5-day average, indicating reduced investor participation. While the stock is currently trading above its shorter-term moving averages, it remains below its 200-day moving average, which could signal potential weakness in the long-term trend.<BR><BR>Overall, while the stock has shown positive short-term performance, the declining investor participation and erratic trading patterns may contribute to a cautious outlook for Chandra Bhagat Pharma Ltd moving forward.

Who are in the management team of Chandra Bhagat?

The management team of Chandra Bhagat includes Hemant C Bhagat (Chairman & Managing Director), Pranav H Bhagat (Whole-time Director), Prachi Pranav Bhagat (Director & CFO), and independent directors Ravindra Gajanan Awati and Abha Praveen Doshi.

The management team of Chandra Bhagat includes the following individuals:<BR><BR>1. **Hemant C Bhagat** - Chairman & Managing Director<BR>2. **Pranav H Bhagat** - Whole-time Director<BR>3. **Prachi Pranav Bhagat** - Director & CFO<BR>4. **Ravindra Gajanan Awati** - Independent Director<BR>5. **Abha Praveen Doshi** - Independent Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

What does Chandra Bhagat do?

Chandra Bhagat Pharma Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2003 and converted to a Public Limited Company in 2019. It has a market cap of INR 38 Cr, with key metrics including a P/E of 12.00 and a debt-equity ratio of 0.36.

Overview: <BR>Chandra Bhagat Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Chandra Bhagat Pharma Limited was incorporated in 2003 as a Private Limited Company and later converted to a Public Limited Company in 2019. There is no recent sales or profit data available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 38 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 12.00 <BR>Industry P/E: 28 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.36 <BR>Return on Equity: 9.27% <BR>Price-to-Book: 1.14 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Chandra Bhagat?

Chandra Bhagat's peers include ANG Lifesciences, Rajnish Wellness, Vista Pharma, Murae Organisor, Roopa Industries, Sandu Pharma, Lasa Supergeneri, JFL Life, and Medicamen Organ. ANG Lifesciences has the highest 1-year return at 20.93%, while Rajnish Wellness has the lowest at -61.17%, with Chandra Bhagat's return at -7.86%.

Peers: The peers of Chandra Bhagat are ANG Lifesciences, Rajnish Wellness, Vista Pharma., Murae Organisor, Roopa Industries, Sandu Pharma., Lasa Supergeneri, JFL Life, and Medicamen Organ.<BR><BR>Quality Snapshot: Below Average management risk is observed at ANG Lifesciences, Vista Pharma., Murae Organisor, Roopa Industries, Lasa Supergeneri, and Medicamen Organ., while Average management risk is found at Rajnish Wellness, Sandu Pharma., and JFL Life. Growth is rated as Excellent at Roopa Industries, Good at Murae Organisor, and Below Average at the rest. Capital Structure is rated as Good at Sandu Pharma., Average at Lasa Supergeneri, and Below Average at the remaining peers.<BR><BR>Return Snapshot: The peer with the highest 1-year return is ANG Lifesciences at 20.93%, while Rajnish Wellness has the lowest at -61.17%. Chandra Bhagat's own 1-year return is -7.86%, which is better than Rajnish Wellness but worse than ANG Lifesciences. Additionally, peers with negative six-month returns include Murae Organisor, Roopa Industries, and Rajnish Wellness.

Which are the latest news on Chandra Bhagat?

When is the next results date for Chandra Bhagat Pharma Ltd?

The next results date for Chandra Bhagat Pharma Ltd is 25 May 2026.

The next results date for Chandra Bhagat Pharma Ltd is scheduled for 25 May 2026.

How has been the historical performance of Chandra Bhagat?

Chandra Bhagat's historical performance shows significant declines in net sales and profits from March 2024 to March 2025, with net sales dropping from 221.37 Cr to 86.72 Cr and increasing debt levels from 16.43 Cr to 20.86 Cr, indicating a challenging financial environment.

Answer:<BR>The historical performance of Chandra Bhagat shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Chandra Bhagat's net sales peaked at 221.37 Cr in March 2024 but dropped to 86.72 Cr by March 2025. The total operating income followed a similar trend, decreasing from 221.37 Cr in March 2024 to 86.72 Cr in March 2025. The total expenditure also saw a decline, from 228.42 Cr in March 2024 to 88.18 Cr in March 2025. Operating profit (PBDIT) was negative in both March 2025 and March 2024, at -1.46 Cr and -7.05 Cr respectively, indicating a challenging operational environment. Profit before tax showed a slight decrease from 2.26 Cr in March 2024 to 1.17 Cr in March 2025, while profit after tax also fell from 1.53 Cr to 0.86 Cr in the same period. The company's total assets remained relatively stable, slightly decreasing from 101.78 Cr in March 2024 to 101.46 Cr in March 2025. Total debt increased from 16.43 Cr to 20.86 Cr, reflecting a rise in financial obligations. Cash flow from operating activities was consistent, with 6.00 Cr in March 2024 and 5.00 Cr in March 2023, but the net cash flow turned negative in March 2024 at -1.00 Cr. Overall, Chandra Bhagat's financial performance indicates a decline in sales and profits, alongside increasing debt levels, suggesting a need for strategic adjustments.

Is Chandra Bhagat overvalued or undervalued?

As of May 30, 2025, Chandra Bhagat's valuation has been downgraded to risky due to overvaluation, with a PE ratio of 42.25 and an EV to EBITDA of -36.70, significantly underperforming its peers and the market.

As of 30 May 2025, the valuation grade for Chandra Bhagat has moved from does not qualify to risky, indicating a significant downgrade in its investment attractiveness. The company is currently considered overvalued, especially when compared to its peers. Key ratios include a PE ratio of 42.25, an EV to EBITDA of -36.70, and a ROE of 3.03%. <BR><BR>In comparison, Sun Pharmaceutical Industries Ltd. has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla Ltd. shows a more favorable PE of 22.99 and an EV to EBITDA of 15.93, both suggesting better valuation metrics. Additionally, Chandra Bhagat's stock has underperformed significantly, with a year-to-date return of -15.15% compared to a 5.58% return for the Sensex, reinforcing the notion that the stock is overvalued in its current state.

What is the technical trend for Chandra Bhagat?

As of June 4, 2025, Chandra Bhagat's technical trend is mildly bearish, with conflicting signals from indicators like the weekly MACD being mildly bullish and the monthly MACD remaining bearish, while daily moving averages also suggest caution.

As of 4 June 2025, the technical trend for Chandra Bhagat has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands and KST are both mildly bearish on the weekly and monthly time frames. The moving averages on the daily chart are bearish, which adds to the overall cautious outlook. The Dow Theory shows a mildly bullish signal on the weekly but is bearish on the monthly. The On-Balance Volume (OBV) is mildly bullish on both weekly and monthly charts, suggesting some accumulation. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and monthly MACD contributing to this view.

Who are the top shareholders of the Chandra Bhagat?

The top shareholders of Chandra Bhagat include Hemant Chandravadan Bhagat with 35.5%, Team Anamika Algo Limited at 9.5%, and individual investors holding 11.16%. There are no pledged promoter holdings or mutual funds invested in the company.

The top shareholders of Chandra Bhagat include the promoters, with Hemant Chandravadan Bhagat holding the largest share at 35.5%. The highest public shareholder is Team Anamika Algo Limited, which owns 9.5%. Additionally, individual investors collectively hold 11.16% of the shares. There is also one foreign institutional investor (FII) that holds 0.61% of the company's shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

how big is Chandra Bhagat?

As of Jun 05, Chandra Bhagat Pharma Ltd has a market capitalization of 46.00 Cr, classifying it as a Micro Cap company. There is no available financial data for the latest four quarters, but as of March 2024, Shareholder's Funds are valued at 29.01 Cr, with Total Assets of 101.78 Cr.

Market Cap: As of Jun 05, Chandra Bhagat Pharma Ltd has a market capitalization of 46.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid Consolidated or Standalone financial data available for the latest four quarters, including figures for Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of March 2024. The Shareholder's Funds are valued at 29.01 Cr, and the Total Assets amount to 101.78 Cr.

Has Chandra Bhagat declared dividend?

No Dividend History Available